Keppra
Memory Impairment
The University of QueenslandPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Memory Impairment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Madopar Peking University Third Hospital | Phase 4 | BB |
Letrozole University of Pennsylvania | Phase 2 | B |
Metformin University of Pennsylvania | Phase 2 | B |
Cot Evon Medics LLC | Phase 2 | CCC |
Cort108297 Johns Hopkins University | Phase 2 | CCC |
PRILOCAINE University of Dublin, Trinity College | Phase 1/2 | CCC |
LIDOCAINE University of Dublin, Trinity College | Phase 1/2 | CCC |
Roflumilast AstraZeneca | Phase 1 | CC |
Same molecule, other indications
Keppra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →